New antibacterial compounds

1:

• A compound of formula (1):
• A-L1-Y-L2-R-B (1)
• wherein
• A is a cyclic group having one of the following formulae (I), (II) and (III)
• wherein
• G1 is CH or N;
• G2 is CR1 or N;
• G3 is CH or N when the dashed line represents a double bond, or CH2, NH or O when the dashed line represents a single bond;
• G4 is CH or N when the dashed line represents a double bond, or CH2, NH or O when the dashed line represents a single bond;
• C1 represents the atoms necessary to form an aliphatic or aromatic six-membered cycle optionally comprising one or more heteroatom selected from nitrogen atom and oxygen atom, said cycle being optionally substituted by one or more substituent selected from the group consisting of halogen atom, (C1-3)alkyl group, cyano group, oxo group (═O), and (C1-3)alkoxy group;
• R1 is hydrogen atom, halogen atom, cyano or (C1-3)alkoxy group;
• L1 is σ bond, or (C1-3)alkylenyl group, optionally substituted with hydroxy group;
• Y is a ring selected from the group consisting of piperidinyl, piperazinyl, pyrrolidinyl, 1-3 cyclobutyl, 1-3 cyclopentyl, 1-2 cyclopropyl, azetidinyl, azabicyclo-octyl, morpholinyl and cyclohexyl ring, said ring being optionally substituted by one or more substituent selected from the group consisting of hydroxy group, (C1-3)alkylenyl-OH group, (C1-3)alkylenyl-O—(C1-3)alkyl group, (C1-3)alkylenyl-CONR′R″ group, and CONR′R″ group, wherein R′ and R″ are hydrogen atom or (C1-3)alkyl;
• L2 is σ bond, —(C1-3)alkylenyl- group, NR′″ group, NR′″—(C1-3)alkylenyl group, (C1-3)alkylenyl-NR′″ group, NR′″—(C1-3)alkylenyl-NR′″ group, or (C1-3)alkylenyl-NR′″—(C1-3)alkylenyl group, said group being optionally substituted with a hydroxy group, wherein R′″ is hydrogen, (C1-3)alkyl, (C1-3)alkylenyl-OH, (C1-3)alkylenyl-O—(C1-3)alkyl, or (C1-3)alkylenyl-CONR′R″, wherein R′ and R″ are hydrogen atom or (C1-3)alkyl;
• R is σ bond or heterocyclic ring, aliphatic or aromatic, having 5 members containing one or more nitrogen atoms, optionally substituted with CH2OH, CH2CN, CN or CONR′R″, wherein R′ and R″ are hydrogen atom or (C1-3)alkyl;
• and
• B is cyclic group having one of the following formulae (IV) to (IX)
• wherein
• G5 is CH or N;
• G6 is CH or N;
• G7 is CH or N;
• G8 is O or NR6;
• R2 is hydrogen atom or halogen atom;
• R3 is hydrogen atom or cyano group, provided that, when R3 is cyano group, A is different from formula (III);
• R4 and R5 are hydrogen atoms;
• R6 is a hydrogen atom or a (C1-3)alkyl group;
• C2 represents the atoms necessary to form a six-membered aliphatic or aromatic heterocycle comprising an oxygen atom or a nitrogen atom;
• C3 represents the atoms necessary to form a six-membered aliphatic heterocycle comprising one oxygen atom and optionally one nitrogen atom, said heterocycle being optionally substituted by one or more substituent selected from the group consisting of (C1-3)haloalkyl group, amido group (—CONH2), and oxo group (═O);
• and
• C4 represents the atoms necessary to form a ten-membered fused bicycle comprising at least one nitrogen atom and at least one other heteroatom selected from oxygen atom and sulfur atom, said bicycle being optionally substituted by one or more substituent selected from the group consisting of halogen atom, (C1-3)alkyl group, cyano group, and oxo group (═O);
• with the proviso that when Y is piperidinyl ring or piperazinyl ring, if A is represented by formula (I) and B is represented by formula (V) or (VI), then G2 is only N,
• or an addition salt with a pharmaceutically acceptable organic or inorganic acid or base, an enantiomer, a N-oxide, or a quaternary ammonium salt of said compound of formula (1).